How to Appeal an Aetna Breast MRI Denial

You just received another Aetna denial for CPT 77049 (Breast MRI), and you're frustrated. Your practice provided quality care, the procedure was medically necessary, but Aetna's initial review team disagreed. The appeal has to show, from the patient's own records, the specific indication that Aetna's breast MRI policy lists.

Why Aetna Denies Breast MRI

Breast MRI codes 77046 through 77049 are on Aetna's 2026 participating provider precertification list, and for most plans the precertification request goes to EviCore healthcare. Check whether the denial cites an EviCore guideline or Aetna's own Clinical Policy Bulletin, and answer the criteria it names. Three common problems:

High-Risk Screening Criteria Not Met: Aetna's Clinical Policy Bulletin 0105, Magnetic Resonance Imaging (MRI) of the Breast, covers screening MRI as an adjunct to mammography only for members at high risk. The listed groups include carriers of a BRCA1 or BRCA2 mutation (beginning at age 25), untested first-degree relatives of a BRCA carrier, carriers of other listed mutations such as TP53, PTEN and PALB2 (each with its own starting age), and members with a lifetime risk of 20 to 25% or more on a standard risk assessment model (the policy names BRCAPRO, Claus, Gail and Tyrer-Cuzick). Radiation to the chest between ages 10 and 30 is a separate listed indication. A record that describes family history but never shows which of these criteria the patient meets leaves the reviewer nothing to approve against.

Insufficient Documentation of Prior Imaging: Most indications in CPB 0105 require a conventional mammogram and/or breast ultrasound within the past year (for high-risk screening, a mammogram within the past year, not required under age 30), so a missing or outdated report invites a denial. For a diagnostic study, the record also needs to show why conventional imaging was not enough, for example inconclusive or conflicting findings on mammography or ultrasound. The policy lists MRI for asymptomatic women with dense breasts and no other risk factor as experimental, so breast density alone will not carry an appeal. Generic statements about "abnormal mammography" will not meet the criteria.

Lack of Treatment Impact Documentation: Perhaps the most overlooked denial reason involves failing to demonstrate how the MRI results will impact patient treatment decisions. CPB 0105 frames its main list of indications as circumstances where the MRI may affect the patient's clinical management. This could involve staging known breast cancer, evaluating treatment response, or screening high-risk patients where early detection would alter surveillance or prevention strategies.

What You Need to Win This Appeal

Successful Aetna breast MRI appeals require specific clinical documentation that directly addresses their coverage criteria. Your appeal package should include comprehensive risk assessment documentation, starting with formal risk calculation tools. Submit the actual output of a risk model showing a lifetime risk of 20 to 25% or more, not just a narrative description of family history. CPB 0105 names BRCAPRO, Claus, Gail and Tyrer-Cuzick (BOADICEA is not on its list). Where you have a choice, use a model built on family history (Tyrer-Cuzick, BRCAPRO or Claus): the American Cancer Society says risk tools that include family history in first- and second-degree relatives on both sides of the family, such as BRCAPRO, should be used to decide who needs MRI screening. The Gail model counts only first-degree relatives, according to the National Cancer Institute's description of the tool, so it does not fit that description.

For genetic predisposition cases, include complete genetic counseling reports and confirmed pathogenic variant testing results. CPB 0105 lists BRCA1/BRCA2, TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome), PALB2 and several other genes, each with its own starting age, so state the gene and the patient's age. Family history documentation should include detailed three-generation pedigrees with specific cancer types, ages at diagnosis, and degree of relationship.

Prior imaging documentation must be comprehensive and specific. Include actual radiology reports from recent mammography and any supplemental breast ultrasound studies, highlighting any finding that was inconclusive or conflicting between studies. CPB 0105 lists breast MRI as experimental for dense breasts alone in an asymptomatic woman with no other risk factor, for a lesion already rated BI-RADS 4 or 5 (which should be biopsied), and for evaluating a patient with atypical ductal hyperplasia, LCIS or DCIS, so do not rest the appeal on those findings. Reference the ACR Appropriateness Criteria for breast imaging when they support the indication, alongside the specific CPB 0105 criterion the patient meets.

Clinical documentation should clearly establish how MRI results will impact treatment decisions. For screening cases, demonstrate that early detection in this high-risk patient would lead to different management compared to standard screening protocols. For diagnostic cases, show how MRI findings will guide surgical planning, evaluate extent of disease, or assess treatment response in ways that conventional imaging cannot achieve.

Step-by-Step: Appealing Your Aetna Breast MRI Denial

Deadlines depend on who is appealing and on the plan. A member of an ACA-compliant commercial or ERISA group health plan, or the provider acting as the member's authorized representative, has at least 180 days from the adverse benefit determination to file an internal appeal. A Medicare Advantage enrollee (or a non-contracted provider with a waiver of liability) has 65 days from the notice to request plan reconsideration. Provider disputes under a participation contract follow the contract. Aetna's disputes and appeals page for providers says claim decisions based on medical necessity skip its reconsideration step and go straight to appeal, with up to 180 days to file for Medicare and commercial plans and up to 65 days for Medicare non-contracted providers; for other disputes, a reconsideration is due within 180 calendar days of the claim decision and an appeal within 60 calendar days of the reconsideration decision. State law and your contract can change these windows, so check the contract and the denial notice before you count days. Missing the deadline can close off the appeal.

Submit written appeals to Aetna's medical review department using the address provided on the denial notice. Include the patient's member ID, dates of service, provider NPI, and reference the original prior authorization or claim number. Your appeal letter should be formatted as a formal medical necessity argument, not a billing dispute—frame the discussion around clinical appropriateness rather than administrative issues.

Structure your appeal letter with clear sections: patient background and risk factors, clinical indication for breast MRI, limitations of conventional imaging, expected treatment impact, and conclusion. Use medical terminology that mirrors Aetna's policy language, such as "high-risk screening indication" or "diagnostic evaluation of extent of disease." Attach supporting documentation as numbered exhibits referenced in your letter.

If the denial was a precertification decision, ask for a peer-to-peer review as soon as it arrives. The terms Aetna shows on its medical Clinical Policy Bulletins page say that, under certain circumstances, the physician may request a peer-to-peer review to discuss a medical necessity precertification determination made by its medical director. If EviCore made the precertification decision, check its notice for how to request one. These conversations can be particularly effective for complex cases where clinical nuance isn't captured in written documentation. Ensure the physician conducting the peer-to-peer review is familiar with current breast imaging guidelines and can articulate the specific medical necessity for MRI over conventional imaging.

Sample Appeal Arguments for Breast MRI Denials

High-Risk Screening Argument: "This 45-year-old patient demonstrates clear indication for high-risk breast cancer screening based on confirmed BRCA2 pathogenic variant (c.5946delT) identified through genetic counseling. Aetna Clinical Policy Bulletin 0105 lists breast MRI, as an adjunct to mammography, as medically necessary for screening members with a confirmed BRCA1 or BRCA2 mutation, beginning at age 25; the patient had a mammogram within the past year [give the date]. Patient's sister diagnosed with invasive ductal carcinoma at age 38, supporting screening initiation. Conventional mammography limitations in premenopausal dense breast tissue (ACR density category D) necessitate MRI for adequate surveillance of this high-penetrance mutation carrier."

Diagnostic Evaluation Argument: "Recently diagnosed invasive lobular carcinoma in the left breast requires MRI evaluation to assess extent of disease and guide surgical planning. Conventional imaging demonstrates 1.8cm mass at 2 o'clock position, but lobular carcinoma's growth pattern frequently results in underestimation of tumor size by mammography and ultrasound. Aetna Clinical Policy Bulletin 0105 lists MRI to map the extent of the primary tumor and identify multicentric disease, and to examine the contralateral breast, in invasive lobular carcinoma as medically necessary. MRI findings will directly impact surgical approach, determining candidacy for breast conservation versus mastectomy."

Treatment Response Assessment Argument: "This 52-year-old patient with locally advanced breast cancer (T3N1M0) has completed neoadjuvant chemotherapy. Clinical examination and conventional imaging show a smaller mass, but they do not define the extent of residual disease well enough to plan surgery. Aetna Clinical Policy Bulletin 0105 lists MRI to assess tumor location, size and extent before and/or after neoadjuvant chemotherapy in locally advanced breast cancer, to determine eligibility for breast conservation therapy, as medically necessary. The MRI will show the size and extent of residual disease and will determine whether the patient is a candidate for breast conservation or needs a mastectomy."

Problem-Solving Argument: "Diagnostic mammography and targeted ultrasound on [dates] produced conflicting findings in the [location] of the [left/right] breast that are not a discrete palpable mass: [describe the finding on each study]. Aetna Clinical Policy Bulletin 0105 lists evaluation of inconclusive or conflicting findings on mammography or ultrasound that is not a discrete palpable mass as a medically necessary indication for breast MRI. The MRI result will determine whether the patient needs a biopsy or can return to routine imaging." Do not use this argument for a lesion already rated BI-RADS 4 or 5, or to evaluate a biopsy result of atypical ductal hyperplasia, LCIS or DCIS: the same policy lists those uses as experimental.

Appeal letter template

Fill in the bracketed fields from the denial letter and the chart, and delete any paragraph that does not apply.

[Practice name]
[Street address, city, state, ZIP]
Phone: [phone] Fax: [fax]
[Date]

[Aetna or EviCore healthcare, as named on the denial notice]
[Appeals address or fax number from the denial notice]

Re: Appeal for [patient name], member ID [member ID], claim number [claim or reference number], date of service [date of service], CPT [77046, 77047, 77048 or 77049, as on the denied claim]

We are writing on behalf of [ordering physician name, credentials] to appeal the denial of breast MRI dated [denial date], which states [denial reason as written in the notice]. We ask that you reconsider this decision and [approve the request or reprocess the claim].

The patient meets the following indication: [for example, a confirmed [gene] pathogenic variant, at age [age]; a lifetime risk of [percent] on [BRCAPRO, Claus, Gail or Tyrer-Cuzick]; radiation to the chest between ages 10 and 30; or inconclusive or conflicting findings on mammography or ultrasound]. The patient had a [mammogram and/or breast ultrasound] on [date], which [describe the findings]. [Explain why conventional imaging was not enough.] The MRI result will [how it changes management, for example surgical planning, extent of disease, or whether a biopsy is needed].

The criteria in [guideline or policy name and number, if the denial cites one] are met, as the enclosed records show; see [page or exhibit references] for each criterion the denial names as unmet.

Enclosures:

• Copy of the denial notice
• Risk model output [model name and lifetime risk, if applicable]
• Genetic counseling report and variant test results [if applicable]
• Three-generation pedigree [if applicable]
• Mammography and ultrasound reports from [dates]
• [Ordering physician's note on how the MRI will change management]

Sincerely,

[Your name]
[Title], on behalf of [ordering physician name, credentials]
[Practice name]
Phone: [phone] Email: [email]

Key Takeaways

• Focus on quantitative risk assessment using validated models rather than general family history statements when supporting high-risk screening indications for CPT 77049
• Document specific limitations of conventional imaging that necessitate breast MRI, attaching the prior imaging reports from the past year (under Aetna's policy, breast density alone is not a covered indication)
• Clearly articulate how MRI results will change clinical management decisions, whether for screening, diagnosis, staging, or treatment response assessment
• Submit appeals within Aetna's specified timeframes with comprehensive clinical documentation and consider peer-to-peer review for complex cases

Tools like AI-powered appeal generators can draft your Breast MRI appeal letter in a few minutes, matching your clinical documentation to Aetna's policy criteria when one is on file.